nach oben

Erschienen in:

01.01.2006 | Symposium Paper

Immunogenic HER-2/neu peptides as tumor vaccines

verfasst von: Constantin N. Baxevanis, Nectaria N. Sotiriadou, Angelos D. Gritzapis, Panagiota A. Sotiropoulou, Sonia A. Perez, Nike T. Cacoullos, Michael Papamichail

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

During the last decade, a large number of tumor-associated antigens (TAA) have been identified, which can be recognized by T cells. This has led to renewed interest in the use of active immunization as a modality for the treatment of cancer. HER-2/neu is a 185-KDa receptor-like glycoprotein that is overexpressed by a variety of tumors including breast, ovarian, lung, prostate and colorectal carcinomata. Several immunogenic HER-2/neu peptides recognized by cytotoxic T lymphocytes (CTL) or helper T lymphocytes (TH) have been identified thus far. Patients with HER-2/neu over-expressing cancers exhibit increased frequencies of peripheral blood T cells recognizing immunogenic HER-2/neu peptides. Various protocols for generating T cell-mediated immune responses specific for HER-2/neu peptides have been examined in pre-clinical models or in clinical trials. Vaccination studies in animals utilizing HER-2/neu peptides have been successful in eliminating tumor growth. In humans, however, although immunological responses have been detected against the peptides used for vaccination, no clinical responses have been described. Because HER-2/neu is a self-antigen, functional immune responses against it may be limited through tolerance mechanisms. Therefore, it would be interesting to determine whether abrogation of tolerance to HER-2/neu using appropriate adjuvants and/or peptide analogs may lead to the development of immune responses to HER-2/neu epitopes that can be of relevance to cancer immunotherapy. Vaccine preparations containing mixtures of HER-2/neu peptides and peptide from other tumor-related antigens might also enhance efficacy of therapeutic vaccination.

Ahmad-Najad P, Hacke H, Rutz M, Bauer S, Vabulas RM, Wagner H (2002) Bacterial DNA and lipopolysaccharides active Toll-like receptors at distinct cellular compartments. Eur J Immunol 32:1958CrossRefPubMed

Amarnath SM, Dyer CE, Ramesh A, Iwuagwu O, Drew PJ, Greenman J (2004) In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer. Int J Oncol 25:211PubMed

Andersen MH, Pedersen LO, Becker JC, Straten PT (2001) Identification of a cytotoxic T lymphocyte reponse to the apoptosis inhibitor protein survirin in cancer patients. Cancer Res 61:869PubMed

Anderson BW, Kudelka AD, Honda T, Pollack MS, Gershenson DM, Gillogly MA, Murray JI, Ioannides CG (2000) Induction of determinant spreading and of TH1 responses by in vitro stimulation with HER-2 peptides. Cancer Immunol Immunother 49:459CrossRefPubMed

Baxevanis CN, Gritzapis AD, Tsitsilonis OE, Katsoulas HL, Papamichail M (2002) HER-2/neu-derived epitopes are also recognized by cytotoxic CD3⁺ CD56⁺ (Natural killer T) lymphocytes. Int J Cancer 98:864CrossRefPubMed

Baxevanis CN, Sotiropoulou PA, Sotiriadou NN, Papamichail M (2004) Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother 53:166CrossRefPubMed

Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M (2000) Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 164:3902PubMed

Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC (1987) The foreign antigen binding site and T cell recognition regions of class I histocompatbility antigens. Nature 329:512CrossRefPubMed

Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC (1987) Structure of the human class I histocompatibility antigen HLA-A2. Nature 329:506CrossRefPubMed

10.

Blackburn EH (1992) Telomerases. Annu Rev Biochem 61:113CrossRefPubMed

11.

Bownds S, Tong-On P, Rosenberg SA, Parkhurst M (2001) Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution. J Immunother 24:1CrossRefPubMed

12.

Brossart P, Stuhler G, Flad T, Stevanovic S, Sammensee HG, Kanz L, Brugger W (1998) HER-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 58:732PubMed

13.

Castilleja A, Carter D, Efferson CL, Ward NE, Kawano K, Fisk B, Kudelka AP, Gershenson DM, Murray JI, O’Brian CA, Ioannides CG (2002) Induciton of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu proton-ogene (369-377) selected by molecular modeling of the peptide HLA-A2 complex. J Immunol 169:3545PubMed

14.

Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chesnut RW, Grey HM, Sette A, Serra HM (1994) Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91:2105PubMed

15.

Chen PW, Ananthaswamy HN (1993) Rejection of K1735 murine melanoma in syngeneic hosts required expression of MHC class I antigens and either class II antigens of IL-2. J Immunol 151:244PubMed

16.

D’Amaro J, Houbiers JG, Drijfhout JW, Brandt RMP, Schipper R, Bavinck JN, Melief CJM, Kast WM (1995) A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs. Hum Immunol 43:13CrossRefPubMed

17.

Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Shiffmann K (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20:2624CrossRefPubMed

18.

Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela Rosa C, Schiffman K (2002) FLt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 99:2845CrossRefPubMed

19.

Eccles SA (2001) The role c-erbB-2/HER-2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 6:393CrossRefPubMed

20.

Engelhard VH (1994) Structure of peptides associated with MHC class I molecules. Curr Opin Immunol 6:13CrossRefPubMed

21.

Ercolini AM, Machiels J-PH, Chen YC, Slansky JE, Giedlen M, Reilly RT, Jaffee EM (2003) Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumor from HER-2/neu-transgenic mice. J Immunol 170:4273PubMed

22.

Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG (1991) Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290CrossRefPubMed

23.

Farina C, Theil D, Semlinger B, Hohlfeld R, Meinl E (2004) Distinct responses of monocytes to Toll-like receptor ligands and imflammatory cytokines. Int Immunol 16:799CrossRefPubMed

24.

Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor- specific cytotoxic T lymphocyte lines. J Exp Med 181:2109CrossRefPubMed

25.

Fisk B, Chesak B, Pollack MS, Wharton JT, Ioannides CG (1994) Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. Cell Immunol 157:415CrossRefPubMed

26.

Fisk B, Hudson JM, Kavanagh J, Wharton JT, Murray JL, Ioannides CG, Kudelka AP (1997) Existent proliferative response of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides. Anticancer Res 17:45PubMed

27.

Fong L, Brockstedt D, Benike C et al Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy from HER-2/neu-transgenic mice. J Immunol 170:4273

28.

Goodison S, Viars C, Urquidi V (2005) Molecular cytogenetic analysis of a human breast metastasis model: identification of phenotype-specific chromosomal rearrangements. Cancer Genet Cytogenet 156:37CrossRefPubMed

29.

Gritzapis AD, Sotiriadou NN, Papamichail M, Baxevanis CN (2004) Generation of human tumor-specific CTLs in HLA-A2.1 trangenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors. Cancer Immunol Immunother 53:1027CrossRefPubMed

30.

Guy CT, Webmaster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic diseases. Proc Natl Acad Sci USA 89:10578PubMed

31.

Hausmann S, Martin M, Gauthier L, Wucherpfennig K (1999) Structural features of autoreactive TCR that determine the degree of degenerary in peptide recognition. J Immunol 162:338PubMed

32.

Hemmi H, Takeuchi O, Kawai T, Kaison T, Sato S, Sanjo H, Mattimoto Hoshino K, Wagner H, Takeda K, Akira SA (2000) Toll-like receptor recognize bacterial DNA. Nature 408:740CrossRefPubMed

33.

Hernandez J, Schoeder P, Blondelle SE, Pons FG, Lone YC, Simora A, Langlade-Demoyen P, Wilson DB, Zanetti M (2004) Antigenicity and immunogenicity of peptide analogues of a low affinity peptide of the human telomerase reverse transcriptase tumor antigen. Eur J Immunol 34:2331CrossRefPubMed

34.

Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, Yoda J, Ikeda H, Hirata K, Yamanaka N, Sato N (2002) An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survirin. Clin Cancer Res 8:1731PubMed

35.

Hori S, Takahashi T, Sakeguchi S (2003) Control of autoimmunity by naturally arising regulatory CD4⁺ T cells. Adv Immunol 81:331PubMed

36.

Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Takashi N (2004) The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 95:697CrossRefPubMed

37.

Ito T, Shiraki K, Sugomoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano Y, Suzuki A (2000) Survirin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31:1080CrossRefPubMed

38.

Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S (1999) Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 154:745PubMed

39.

Kawai K, Ohashi PS (1995) Immunological function of a defined T cell population tolerized to low-affinity self antigens. Nature 374:68CrossRefPubMed

40.

Kawakami Y, Eliyadu S, Sakaguchi K, Robbins PF, Rivoltini I, Yannelli JR, Apella E, Rosenberg SA (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180:347CrossRefPubMed

41.

Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E (1998) The multiepitope approach for immunotherapy of cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 59:1CrossRefPubMed

42.

Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E (1999) Identification of HLA-A3-restricted cytotoxic T lymphocytes epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res 59:431PubMed

43.

Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A (2001) Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol 167:787PubMed

44.

Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM, Vissers DC, ten Bosch GJ, Kester MG, Sijts A, Drijfhout JW, Ossendorp F, Offringa R, Melief CJM (2001) Efficient identification of novel HLA-A*0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 193:73CrossRefPubMed

45.

Kiessling R, Wel WZ, Herrmann F, Lindencrona JA, Cheudhury A, Kono K, Seliger B (2002) Cellular immunity to the HER-2/neu protooncogene. Adv Cancer Res 85:101PubMedCrossRef

46.

Kim NW (1997) Clinical implications of telomerase in cancer. Eur J Cancer 33:781CrossRefPubMed

47.

Knutson KL, Shiftmann K, Cheever MA, Disis ML (2002) Immunization of cancer patients with a HER-2/neu. HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 8:1014PubMed

48.

Knutson KL, Shiftmann K, Disis ML (2001) Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity to cancer patients. J Clin Invest 107: 477PubMedCrossRef

49.

Kobayashi H, Wood M, Song Y, Appelle E, Celis E (2000) Defining promiscuous MHC class II helper T-cell epitopes for HER-2/neu tumor antigen. Cancer Res 60:52258

50.

Kondo A, Sidney J, Southwood S, del Guercio MF, Appella E, Sakamoto H, Celis E, Grey HM, Chesnut RW, Kubo RT (1995) Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. J Immunol 155:4307PubMed

51.

Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, Appellia E, Sekikawa T, Matshumoto Y, Kiessling R (1998) Identification of HER-2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 78:202CrossRefPubMed

52.

Kuhns JJ, Batalia MA, Shuqin Y, Collins EJ (1999) Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is dues to a lack of interaction with the center of the peptide. J Biol Chem 274:26422CrossRef

53.

Bohlen P, Hicklin DJ (2003)Vaccination against angiogenesis-associated antigens: a novel cancer immunotherapy strategy. Curr Mol Med 3:773. ReviewCrossRefPubMed

54.

Liu J-Y, Wei Y, Yang L, Zhao X,, Tian L, Hou J, Niu Y, Liu F, Jiang Y, Xu B, Wy Y, Su J, Lou Y, He Q, Wen Y, Yang J, Kan B, Mao Y, Luo F, Peng F (2003) Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 102:1815CrossRefPubMed

55.

Lustgarten L, Dominguez AL, Guadros C (2004) The CD8+ T cell repertoire against HER-2/neu antigens in new transgenic mice is of low avidity with antitumor activity. Eur J Immunol 34:752CrossRefPubMed

56.

Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, Cheever MA, Sherman LA (1997) Identification of HER-2/neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8. Hum Immunol52:109CrossRefPubMed

57.

Morel S, Levy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M, Peitrequin Al, Monsarrat B, Van Veithove R, Cerottini JC, Boon T, Gairin JE, Van den Eynde BJ (2000) Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12:107CrossRefPubMed

58.

Morgan DK, Kreuwell HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA(1998) Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol 160:643PubMed

59.

Moriai R, Asanuma K, Kobayashi D, Yajima T, Yagihashi A, Yamada M, Watanabe N. Quantitative analysis of this anti-apoptotic gene survivin-expression in malignant haematopoietic cells. Anticancer Res 21:595

60.

Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:104CrossRef

61.

Mullins DW, Bullock TN, Colella TA, Robila VV, Engelhard VH (2001) Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201- transgenic mice. J Immunol 167:4853PubMed

62.

Murray JL, Przepiorka D, Ioannides C (2000) Clinical trials of HER-2/neu-specific vaccines. Semin Oncol 27:71PubMed

63.

Nakamura TM, Morin GH, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR (1997) Science 277:955CrossRefPubMed

64.

Niethammer AG, Xiang R, Becker JC, Wodrsch H, Derte U, Karsten G, Eliceiri BP, Reisfeld RA (2002) A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8:1369CrossRefPubMed

65.

Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP (1998) gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 188:277CrossRefPubMed

66.

Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR (1990) Pathologic findings from the National Surgical Adjuvant Breast and Bowell Project:prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103PubMed

67.

Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163PubMed

68.

Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA (2004) Immunization of patients with hTERT: 540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing tolemerase. Clin Cancer Res 15:4688CrossRef

69.

Peiper M, Goedegebuure MP, Linehan DC, Ganguly E, Douville CC, Eberlein TJ (1997) The HER-2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Eur J Immunol 27:1115PubMed

70.

Perez SA, Sotiropoulou PA, Sotiriadou NM, Mamalaki A, Gritzapis AD, Echner H, Voelter W, Pawelec G, Papamichail M, Baxevanis CN (2002) HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4⁺ T cell clones. Cancer Immunol Immunother 50:615CrossRefPubMed

71.

Plum SM, Fogmer WE (2004) Anti-angiogenic vaccines as a treatment modality for cancer. Curr Opin Investig Drugs 5:1243PubMed

72.

Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213CrossRefPubMed

73.

Reisfeld RA, Niethammer AG, Luo Y, Xiang R (2004) DNA vaccines suppress tumor growth and metastases by the induction of anti-angiogenesis. Immunol Rev 199:181CrossRefPubMed

74.

Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, Andersein MH (2004) Identification of novel survirin-derived CTL epitopes. Cancer Biol Ther 3:173PubMed

75.

Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be temporal bridge between a CD4⁺ T-helper and a T-killer cell. Nature 393:474CrossRefPubMed

76.

Rivoltini L, Squarcina P, Loftus DJ, Castelli C, Tarsini P, Mazzocchi A, Rini F, Viggiano V, Belli F, Parmiani G (1999) A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8⁺ T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res 39:301

77.

Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Komo K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R (1999) Identification of new HER-2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163:1037PubMed

78.

Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A (1993) Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules.Cell 74:929CrossRefPubMed

79.

Salazar E, Zaremba S, Arlen PM, Tsang KY, Schlom J (2000) Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of TC1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. Int J Cancer 85:829CrossRefPubMed

80.

Sanchez-Garcia L, Grutz G (1995) Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA 92:5287PubMed

81.

Scardino A, Alves P, Gross DA, Tourdot S, Graff-Dubois S, Angevin E, Firat H, Chouaib S, Lemonnier F, Nadler LM, Cardoso AA, Kosmatopoulos K (2001)Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur J Immunol 31:3261CrossRefPubMed

82.

Scardino A, Gross D-A, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kospatopoulos K (2002) HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168:5900PubMed

83.

Schoenberger PS, Toes RE, van der Voort EI, Offringa R, Melief CJM (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480CrossRefPubMed

84.

Sercarz EE (2000) Driver clones and determinant spreading. J Autoimmun 14:275CrossRefPubMed

85.

Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K (1993) Dominance and crypticity of T-cell antigenic determinants. Ann Rev Immunol 11:729CrossRef

86.

Serody JS, Collins EJ, Tisch RM, Kuhns JJ, Freilinger JA (2000) T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery. J Immunol 164:4961PubMed

87.

Shiku H, Wang L, Ikuta Y, Okugawa T, Schmitt M, Gu X, Akiyoshi K, Sunamoto J, Nakamura H (2000) Development of a cancer vaccine: peptides, proteins and DNA. Cancer Chemother Pharmacol 46:77CrossRef

88.

Sidney J, Southwood S, del Guercio MF, Grey HM, Chesnut RW, Kubo RT, Sette A (1996) Specificity and degenerary in peptide binding to HLA-B7-like class I molecules. J Immunol 157:3480PubMed

89.

Slansky JE, Rattis FM, Boyd IF, Fahmy T, Jaffee EM, Schneck JP, Margulles DH, Pardoll DM (2000) Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13:529CrossRefPubMed

90.

Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC (2001) Urine detection of survirin and diagnosis of bladder cancer. J Am Med Assoc 285:324CrossRef

91.

Sotiriadou R, Perez SA, Gritzapis AD, Sotiropoulou PA, Echner H, Heinzel S, Mamalaki A, Pawelec G, Voelter W, Baxevanis CN, Papamichail M (2001) Peptide HER2 (776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer 85:1527CrossRefPubMed

92.

Sotiropoulou PA, Perez SA, Hliopoulou EG, Missitzis I, Voelter W, Echner H, Baxevanis CN, Papamichail M (2003) Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu-positive epithelial tumors. Br J Cancer 80:1055CrossRef

93.

Sotiropoulou PA, Perez SA, Voelter W, Echner H, Missitzis I, Tsavaris NB, Papamichail M, Baxevanis CN (2003) Natural CD8⁺ T cell responses against MHC class I epitopes of the HER-2/neu oncoprotein in patients with epithelial tumors. Cancer Immunol Immunother 52:771CrossRefPubMed

94.

Tajima K, Ito Y, Demachi A, Nishida K, Akatsuka Y, Tsujimura K, Hida T, Morishima Y, Kuwano H, Mitsudomi T, Takahashi T, Kuzushima K (2004) Interferon-gamma differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes. Int J Cancer 20:403CrossRef

95.

Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6:127PubMed

96.

Titu LV, Loveday RL, Maden LA, Cawkwell L, Monson JR, Greenman J (2004) Cytotoxic T-cell immunity against telomerase reverse transcriptase in colorectal cancer patients. Oncol Rep 12:871PubMed

97.

Thomas DG, Giordano TJ, Sanders D, Biermann S, Sondak UK, Trent JC, Pollock RE, Baker L (2005) Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 103:830CrossRefPubMed

98.

Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A, Celis E (1997) Identification of subdominant CTL epitopes of the gp100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol 158:1796PubMed

99.

Tuttle TM, Anderson BW, Thompson WE, Lee JE, Sahin A, Smith Tl, Grabstein KH, Wharton T, Ioannides CG, Murray JL (1998) Proliferative and cytokine reponses to class II HER-2/neu-associated peptides in breast cancer. Clin Cancer Res 4:2015PubMed

100.

Valmori D, Levy F, Miconnet I, Zajac P, Spagnoli GC, Rimold D, Lienard D, Cerrundolo J, Cerrotini C, Romero P (2000) Induction of potent antitumor CTL responses by recombinant vaccinia encoding a Melan-peptide analogue. J Immunol 164:1125PubMed

101.

Vertuani S, Sette A, Sidney J, Southwood S, Fikes J, Keogh E, Lindencrona JA, Ishioka G, Levitskaya J, Kiessling R (2004) Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues. J Immunol 172:3501PubMed

102.

Watson MB, Bahia H, Ashman JN, Berrieman HK, Drew P, Lind MJ, Greenman J, Cawkwell L (2004) Chromosomal alterations in breast cancer revealed by multicolour fluorescence in situ hybridization. Int J Oncol 25:277PubMed

103.

Wang RF (1999) Human tumor antigens: implications for cancer vaccine development. J Mol Med 77:640CrossRefPubMed

104.

Wei YQ, Huang MJ, Yang L, Zhao X, Thian L, Lu Y, Shu JM, Lu CJ, Niu T, Kang B, Mao YQ et al (2001) Immunogene therapy of tumours with vaccine based on xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 98:11545CrossRefPubMed

105.

Williams NS, Gaynor RB, Scoggin S, Verna U, Gokaslan T, Simmang C, Flemming J, Tavana D, Frenkel E, Becerra C (2003) Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 9:931PubMed

106.

Worley BS, van den Broeke IT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzolsky JA (2001) Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res 61:6868PubMed

107.

Yi H, Fujimura Y, Ouchida M, Prasad DD, Rao VN, Reddy ES (1997) Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in human solid tumors and leukemias. Oncogene 14:1259CrossRefPubMed

108.

Yoshimura A, Shiku H, Nakayama E (1993) Rejection of an IA⁺ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4⁺ and CD4⁻ CD8⁺ T cell receptor-αβ phenotypes generated in CD8-depleted C57BL/6 mice. J Immunol 150:4900PubMed

109.

Zaks TZ, Rosenberg SA (1998) Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 58:4902PubMed

Titel: Immunogenic HER-2/neu peptides as tumor vaccines
verfasst von: Constantin N. Baxevanis
Nectaria N. Sotiriadou
Angelos D. Gritzapis
Panagiota A. Sotiropoulou
Sonia A. Perez
Nike T. Cacoullos
Michael Papamichail
Publikationsdatum: 01.01.2006
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 1/2006
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-005-0692-3

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Immunogenic HER-2/neu peptides as tumor vaccines

Abstract

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Das sind die führenden Symptome junger Darmkrebspatienten

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2006

Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin

Dendritic cell-based cancer immunotherapy targeting MUC-1

Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type

Release of iC3b from apoptotic tumor cells induces tolerance by binding to immature dendritic cells in vitro and in vivo

Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy

Characterization of glycosylation and adherent properties of melanoma cell lines

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

Das sind die führenden Symptome junger Darmkrebspatienten

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

Update Onkologie